Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers

BackgroundNovel and targetable mutations are needed for improved understanding and treatment of lung cancer in never-smokers.MethodsTwenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor phenotypes and clinical outcomes.ResultsAlthough somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9, PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with pathway deregulation and patient survival.ConclusionsThe recurrent mutations present in both DNA and RNA are likely the driver for tumor biology, pathway deregulation and clinical outcomes. The information may be used for patient stratification and therapeutic target development.

[1]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[2]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[3]  Isabel Polanco,et al.  Interleukin-10 haplotypes in Celiac Disease in the Spanish population , 2006, BMC Medical Genetics.

[4]  G. Viglietto,et al.  The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. , 2012, The American journal of pathology.

[5]  S. Ghadiali,et al.  Myoferlin Depletion in Breast Cancer Cells Promotes Mesenchymal to Epithelial Shape Change and Stalls Invasion , 2012, PloS one.

[6]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[7]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[8]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[9]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[10]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[11]  Elin Karlsson,et al.  Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer , 2011, Breast Cancer Research and Treatment.

[12]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[13]  Michal Sheffer,et al.  Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.

[14]  W. Pao,et al.  Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis , 2012, Clinical Cancer Research.

[15]  G. V. Ommen,et al.  Medical genomics , 2001, European Journal of Human Genetics.

[16]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[17]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[18]  R. Wolff,et al.  Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. , 2011, Mutation research.

[19]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[20]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[21]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[22]  S. Goodison,et al.  Targeting Sp1 transcription factors in prostate cancer therapy. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[23]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[24]  Ying Li,et al.  TREAT: a bioinformatics tool for variant annotations and visualizations in targeted and exome sequencing data , 2011, Bioinform..

[25]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[26]  Kevin P. Murphy,et al.  SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors , 2010, Bioinform..

[27]  Avner Friedman,et al.  Mechanistic modeling of the effects of myoferlin on tumor cell invasion , 2011, Proceedings of the National Academy of Sciences.

[28]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[29]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..